Cancer Family
Intestinal Neoplasm
CI-CAN-00000209Explore in graph →
Non-malignant1,893 active trials21 approved drugs383 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000209Explore in graph →
Clinical trials
9,158 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07523763 | Neoadjuvant Low-dose Immunotherapy in Locally Advanced MMR-deficient Colorectal Cancer(NIVO1002024) | active not recruiting | Phase 2 | 30 | Blokhin's Russian Cancer Research CenterOTHER | 1 | Apr 17, 2026 | clinicaltrials |
| NCT07535632 | SBRT Followed by PD-1 Inhibitor, Bevacizumab and TAS-102 as Third-Line Therapy for Recurrent/Metastatic Colorectal Cancer(BEST) | not yet recruiting | Phase 2 | 58 | Shanghai Zhongshan HospitalOTHER |
| 1 |
| Apr 17, 2026 |
| clinicaltrials |
| NCT07537998 | Antegrade Intestinal Fluid Reinfusion for Prevention of Low Anterior Resection Syndrome After Low Anterior Resection: a Single-Center, Prospective Randomized Controlled Trial. | recruiting | Phase 2 / Phase 3 | 160 | Pei-Rong DingOTHER | 1 | Apr 17, 2026 | clinicaltrials |
| NCT03157128 | A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)(LIBRETTO-001) | active not recruiting | Phase 1 / Phase 2 | 857 | Eli Lilly and CompanyINDUSTRY | 16 | Apr 16, 2026 | clinicaltrials |
| NCT06569368 | Trial Utilizing Metronidazole to Optimize the Microbiome of Rectal Adenocarcinoma Undergoing Neoadjuvant Therapy | recruiting | Phase 2 | 60 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 16, 2026 | clinicaltrials |
| NCT06638931 | Agnostic Therapy in Rare Solid Tumors(ANTARES) | recruiting | Phase 2 | 28 | Instituto do Cancer do Estado de São PauloOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT06669572 | Lenvatinib and Pembrolizumab to Treat Patients With Anal or Rectum Cancer That Has Gotten Worse After Initial Treatment | recruiting | Phase 2 | 35 | University of ChicagoOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT07353645 | KRAS Neoantigen Nanovaccine as Adjuvant Therapy for Colorectal Cancer/Pancreatic Cancer | recruiting | Phase 1 / Phase 2 | 49 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT07527026 | A Single-arm Phase II Clinical Study of Camrelizumab Combined With Long-course Chemoradiotherapy for Total Neoadjuvant Therapy in Locally Advanced Low pMMR/MSS Rectal Cancer | recruiting | Phase 2 | 44 | Chinese PLA General HospitalOTHER | 1 | Apr 14, 2026 | clinicaltrials |
| NCT07527520 | Neoadjuvant Moderately Hypofractionated Radiotherapy Combined With Chemotherapy and Immunotherapy for High-risk pMMR/MSS Locally Advanced Rectal Cancer: A Prospective, Multi-center Randomized Control Phase II Trial | not yet recruiting | Phase 2 | 165 | Fudan UniversityOTHER | 1 | Apr 14, 2026 | clinicaltrials |
| NCT02688712 | ExIST Study of LY2157299 (Galunisertib) in Rectal Cancer | active not recruiting | Phase 2 | 50 | Providence Health & ServicesOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT06362369 | A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy | recruiting | Phase 1 / Phase 2 | 126 | 7 Hills Pharma, LLCINDUSTRY | 1 | Apr 13, 2026 | clinicaltrials |
| NCT06417476 | Short-course Radiotherapy or Long-course Chemoradiation Followed by mFOLFOXIRI Consolidation Chemotherapy for Organ Preservation in Low Rectal Cancer | active not recruiting | Phase 2 | 66 | Pei-Rong DingOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT07042685 | Trial of 5-Fluorouracil (5FU)-Based Therapy in Combination With Fruquintinib in Patients With Locally Advanced Unresectable or Metastatic Colorectal Cancer | recruiting | Phase 2 | 50 | The Methodist Hospital Research InstituteOTHER | 1 | Apr 9, 2026 | clinicaltrials |
| NCT06162650 | Total Neoadjuvant Therapy in Rectal Cancer | recruiting | Phase 2 | 42 | National Cheng-Kung University HospitalOTHER | 1 | Apr 8, 2026 | clinicaltrials |
| NCT07506109 | A Phase II Study of Sintilimab Combined With Ipilimumab N01, Cetuximab and Dabrafenib in Patients With Microsatellite-Stable, BRAF V600E-Mutated Metastatic Colorectal Cancer | recruiting | Phase 2 | 49 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Apr 7, 2026 | clinicaltrials |
| NCT07515820 | SHR-3821 in Advanced Colorectal Cancer: an Exploratory Study | not yet recruiting | Phase 2 | 12 | Meng QiuOTHER | 0 | Apr 7, 2026 | clinicaltrials |
| NCT07516210 | Adaptive Radiotherapy for Safe Hypofractionation(ART-Hypo) | not yet recruiting | Phase 2 | 264 | Centre hospitalier de l'Université de Montréal (CHUM)OTHER | 1 | Apr 7, 2026 | clinicaltrials |
| NCT07510932 | Fruquintinib In Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies in South Korea Patients (FIRST-K)(FIRST-K) | not yet recruiting | Phase 2 | 88 | Korea University Anam HospitalOTHER | 0 | Apr 6, 2026 | clinicaltrials |
| NCT03678883 | 9-ING-41 in Patients With Advanced Cancers | active not recruiting | Phase 2 | 350 | Actuate Therapeutics Inc.INDUSTRY | 7 | Apr 3, 2026 | clinicaltrials |
| NCT04245865 | Tocotrienol and Bevacizumab in Metastatic Colorectal Cancer(Toco-CoR) | active not recruiting | Phase 2 | 83 | Vejle HospitalOTHER | 1 | Apr 3, 2026 | clinicaltrials |
| NCT06281405 | CAPOX and PD-1 Antibody Combined With or Without Radiotherapy for MSS Locally Advanced Rectal Cancer(TORCH-iTNT) | recruiting | Phase 2 | 192 | Fudan UniversityOTHER | 1 | Apr 3, 2026 | clinicaltrials |
| NCT07509398 | FMT Combined With Standard First-Line Therapy in Initially Unresectable Colorectal Cancer | not yet recruiting | Phase 2 / Phase 3 | 220 | Shanghai 10th People's HospitalOTHER | 0 | Apr 3, 2026 | clinicaltrials |
| NCT07509424 | Neoadjuvant Short-course Radiotherapy Followed by a Combination of Disitamab Vedotin, Sintilimab, and Capecitabine in Locally Advanced HER2-expressing Rectal Cance | not yet recruiting | Phase 2 | 29 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 0 | Apr 3, 2026 | clinicaltrials |
| NCT06553885 | Ph II Study of Enfortumab Vedotin in Patients With Advanced or Metastatic CRC or HCC | recruiting | Phase 2 | 40 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Apr 1, 2026 | clinicaltrials |
| NCT07033026 | An Evaluation of NGM120 in a Randomized, Double-blind, Placebo-controlled Study in Participants With Colorectal Cancer Who Have Cancer Cachexia. | recruiting | Phase 2 | 136 | NGM Biopharmaceuticals, IncINDUSTRY | 4 | Apr 1, 2026 | clinicaltrials |
| NCT07505472 | Efficacy and Safety Comparison of Short-course Radiotherapy Followed by CapeOX Chemotherapy Plus Toripalimab With or Without Concurrent Surufatinib in Neoadjuvant Therapy for Mid-to-low Localized Rectal Cancer of High-risk Criteria(STARS-RC10) | recruiting | Phase 2 / Phase 3 | 212 | The First Hospital of Jilin UniversityOTHER | 1 | Apr 1, 2026 | clinicaltrials |
| NCT04963283 | Study of Cabozantinib and Nivolumab in Refractory Metastatic Microsatellite Stable (MSS) Colorectal Cancer | active not recruiting | Phase 2 | 48 | University of Colorado, DenverOTHER | 1 | Mar 31, 2026 | clinicaltrials |
| NCT06634875 | Isunakinra Alone and in Combination With Pembrolizumab in Patients With Colorectal Cancer (MSS) | recruiting | Phase 2 | 20 | Buzzard PharmaceuticalsINDUSTRY | 1 | Mar 31, 2026 | clinicaltrials |
| NCT07503639 | Umbrella Trial of Neoadjuvant Therapy for Locally Advanced Colorectal Cancer | not yet recruiting | Phase 2 | 134 | Fudan UniversityOTHER | 0 | Mar 31, 2026 | clinicaltrials |
| NCT07504263 | Phase 1/2a Study of RP-001 in Participants With Advanced Malignancies | not yet recruiting | Phase 1 / Phase 2 | 66 | Recurv Pharma IncINDUSTRY | 0 | Mar 31, 2026 | clinicaltrials |
| NCT07502014 | A Clinical Study of Iparomlimab and Tuvonralimab Combined With Fruquintinib and Heterogeneous Radiotherapy Versus Fruquintinib as Third-Line and Subsequent-Line Treatment for Metastatic Colorectal Cancer | not yet recruiting | Phase 2 | 60 | Huazhong University of Science and TechnologyOTHER | 0 | Mar 30, 2026 | clinicaltrials |
| NCT06395519 | A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies(ERADIC8) | recruiting | Phase 1 / Phase 2 | 120 | 858 Therapeutics, Inc.INDUSTRY | 1 | Mar 27, 2026 | clinicaltrials |
| NCT06850103 | SCRT-CAPEOX-Serplulimab for MSS/pMMR Rectal Cancer With Oligometastases | recruiting | Phase 2 | 51 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Mar 25, 2026 | clinicaltrials |
| NCT02758951 | Perioperative Systemic Therapy for Isolated Resectable Colorectal Peritoneal Metastases(CAIRO6) | active not recruiting | Phase 2 / Phase 3 | 358 | Koen RoversOTHER | 2 | Mar 24, 2026 | clinicaltrials |
| NCT04008797 | A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor | active not recruiting | Phase 1 / Phase 2 | 301 | Eisai Inc.INDUSTRY | 10 | Mar 24, 2026 | clinicaltrials |
| NCT07491159 | Fruquintinib Plus Checkpoint Inhibitor Combined or Sequential TAS-102 in Colorectal Cancer Patients Who Progressed on Second-line Standard Therapy: a Prospective, Multi-cohort, Single-centered, Phase Ib/II Study | active not recruiting | Phase 1 / Phase 2 | 106 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Mar 24, 2026 | clinicaltrials |
| NCT03654131 | Microwave Ablation Versus Stereotactic Body Radiotherapy for Colorectal Liver Metastases in Oligometastatic Disease: a Prospective, Randomised, Phase 2 Trial(LAVA-CRLM) | active not recruiting | Phase 2 | 100 | Rigshospitalet, DenmarkOTHER | 1 | Mar 19, 2026 | clinicaltrials |
| NCT05179889 | Adjuvant mFOLFIRINOX for High-risk Stage III Colon Cancer | recruiting | Phase 2 / Phase 3 | 308 | Chungnam National University HospitalOTHER | 1 | Mar 19, 2026 | clinicaltrials |
| NCT04699188 | Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation(KontRASt-01) | active not recruiting | Phase 1 / Phase 2 | 344 | Novartis PharmaceuticalsINDUSTRY | 16 | Mar 18, 2026 | clinicaltrials |
| NCT05806931 | Sequential TAS-OX Alternating With TAS-IRI Plus Bevacizumab for Late-Line Metastatic Colorectal Cancer(SCOTI) | recruiting | Phase 2 | 50 | Rutgers, The State University of New JerseyOTHER | 1 | Mar 18, 2026 | clinicaltrials |
| NCT06244771 | A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors(PROSPER) | recruiting | Phase 1 / Phase 2 | 403 | Frontier Medicines CorporationINDUSTRY | 3 | Mar 18, 2026 | clinicaltrials |
| NCT07478731 | Neoadjuvant SHR-1701 Plus Chemoradiotherapy for Locally Advanced Rectal Cancer(MA-CRC-II-018) | recruiting | Phase 2 | 48 | Hong QiuOTHER | 1 | Mar 17, 2026 | clinicaltrials |
| NCT05194995 | JAB-21822 in Combination With Cetuximab in Patients With Advanced CRC and Other Solid Tumors With KRAS G12C Mutation | active not recruiting | Phase 1 / Phase 2 | 48 | Allist Pharmaceuticals, Inc.INDUSTRY | 1 | Mar 16, 2026 | clinicaltrials |
| NCT07469306 | Short-Course RT Plus CAPOX and Tislelizumab vs Long-Course CRT Plus Tislelizumab for Locally Advanced Rectal Cancer | not yet recruiting | Phase 2 | 130 | Fujian Cancer HospitalOTHER_GOV | 1 | Mar 13, 2026 | clinicaltrials |
| NCT07467590 | Combination of High and Low-Dose Radiotherapy With Immune Therapy and TKI in Advanced Colorectal Cancer: A Phase II Study(TRIUNITE-07) | not yet recruiting | Phase 2 | 33 | Daping Hospital and the Research Institute of Surgery of the Third Military Medical UniversityOTHER | 0 | Mar 12, 2026 | clinicaltrials |
| NCT07468630 | Tolecizumab Plus Chemoimmunotherapy for pMMR/MSS Locally Advanced Colon Adenocarcinoma(TRIUNITE-08) | recruiting | Phase 2 | 106 | Daping Hospital and the Research Institute of Surgery of the Third Military Medical UniversityOTHER | 1 | Mar 12, 2026 | clinicaltrials |
| NCT07463599 | Safety and Efficacy of Tegavivint in Patients With Metastatic Colorectal Carcinoma | recruiting | Phase 1 / Phase 2 | 126 | HonorHealth Research InstituteOTHER | 1 | Mar 11, 2026 | clinicaltrials |
| NCT07458529 | Neoadjuvant Chemoradiotherapy Plus Tislelizumab With or Without Probio-M9 in pMMR/MSS Locally Advanced Rectal Cancer(NCRIT-PM9) | recruiting | Phase 2 | 50 | Seventh Medical Center of PLA General HospitalOTHER | 1 | Mar 10, 2026 | clinicaltrials |
| NCT07462650 | Dual-Target CAR-NK Cells for Biomarker-Selected Advanced Colorectal Cancer | recruiting | Phase 1 / Phase 2 | 48 | Beijing BiotechINDUSTRY | 1 | Mar 10, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Apr 17, 2026source: clinicaltrials